Note 16 - Segments (Tables)

12 Months Ended

Dec. 31, 2020

Year Ended December 31, 2020	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	7,995		$	—		$	—		$	7,995
License revenue		110,730			—			—			110,730
Grant and other revenue		482,221			314,067			—			796,288
Total revenue		600,946			314,067			—			915,013
Cost of revenue		1,048			—			—			1,048
Research and development expenses		4,593,459			336,728			—			4,930,187
Selling, general and administrative expenses, excluding depreciation and amortization (1)		299,959			800			6,323,807			6,624,566
Depreciation and amortization (2)		10,068			—			60,325			70,393
Loss from operations (3)		(4,303,588	)		(23,461	)		(6,384,132	)		(10,711,181	)
Other expense (4)		—			—			(10,510	)		(10,510	)
Net loss		(4,303,588	)		(23,461	)		(6,394,642	)		(10,721,691	)
Total assets, net of depreciation and amortization:
United States	$	139,121			—			7,416,106			7,555,227
International		202,791			—			—			202,791
Capital expenditures		120,810			—			15,071			135,881

Year Ended December 31, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	16,665		$	—		$	—		$	16,665
License revenue		9,953			—			—			9,953
Grant and other revenue		384,776			246,432			—			631,208
Total revenue		411,394			246,432			—			657,826
Cost of revenue		6,667			—			—			6,667
Research and development expenses, excluding depreciation and amortization		4,795,445			542,822			—			5,338,267
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			16,990			6,113,907			6,130,897
Depreciation and amortization (2)		—			—			144,512			144,512
Loss from operations (3)		(4,390,718	)		(313,380	)		(6,258,419	)		(10,962,517	)
Other income (4)		—			—			17,675			17,675
Provision for income taxes		(284	)		(20	)		(403	)		(707	)
Loss from continuing operations		(4,391,002	)		(313,400	)		(6,241,147	)		(10,945,549	)
Loss from discontinued operations, net of tax effect		(2,665	)		—			—			(2,665	)
Net loss		(4,393,666	)		(313,400	)		(6,241,147	)		(10,948,214	)
Total assets, net of depreciation and amortization:
United States	$	55,229		$	31,449		$	4,064,228		$	4,150,906
International		—			—			—			—
Capital expenditures		—			—			1,258			1,258